Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Ahlstrom-Munksjö to repurchase own shares

AHLSTROM-MUNKSJÖ OYJ STOCK EXCHANGE RELEASE FEBRUARY 13, 2020 at 10:00 a.m. EET  The Board of Directors of Ahlstrom-Munksjö Oyj has decided to utilize the current authorization given by the Annual General Meeting (AGM) held on March 27, 2019 to repurchase own shares. The authorization, to acquire a maximum of 11,500,000 of the company's own shares, is valid until the end of the AGM 2020 to be held on March 25, 2020. The repurchases will start at the earliest on February 18, 2020 and end on March 24, 2020 at the latest. The amount of shares to be acquired shall not exceed 300,000

Mandatory Notification of Trade - Options

Reference is made to the announcement on 5 April, 2017, in which Hexagon Composites ASA (the "Company") announced the grant of 1,640,000 share options to employees under its employee share option program, each at a strike price of NOK 27 per share. Of the 1,640,000 options, 1,175,000 options were granted to senior executives and managers listed as primary insiders. The options may be exercised in part or in full within three weeks following the official announcement of the financial results for the fourth quarter of 2019, first quarter of 2020 and second quarter of 2020. Primary

CLINE SCIENTIFIC HAS STARTED TESTING THEIR DIAGNOSTIC PROTOTYPE FOR METASTASIZING CANCERS ON LIVE PATIENT MATERIAL WITH CLINICAL RESEARCHERS AT A SWEDISH HOSPITAL

Gothenburg, Sweden (February 13 2020):  Cline Scientific will have begun to utilize live tumor cells directly from cancer patients to develop and test their diagnostic prototype for metastasizing cancers to bring this technology to marketThe tumor cells originate from biopsies taken from patients with benign or metastatic tumors. Cline’s prototype has shown promising results in differentiating metastatic from benign tumor cells. Testing on live patient material is a necessary technical step to test how cells from patient biopsies behave before the company is able to initiate clinical

New plan periods in the share-based long-term plans and a new matching share plan for Ahlstrom-Munksjö

AHLSTROM-MUNKSJÖ OYJ STOCK EXCHANGE RELEASE February 13, 2020, at 9:45 a.m. EET Ahlstrom-Munksjö's Board of Directors has decided on a new performance period under the long-term share-based incentive plan announced on October 24, 2017. The Board of Directors has, in addition, decided on the establishment of a fixed matching share plan as well as on the establishment of a new earning period in the restricted share plan that was announced in March 28, 2019. The aim of the plans is to align the objectives of the company's shareholders and key personnel to increase the company's value and to

ENDOMINES Year-end report 2019 Ramp-up of Friday continued succesfully

Endomines AB, Stock Exchange Release 13 February 2020 at 08:30 CET Full year 2019 (vs. Full year 2018) Operational highlights · Friday Orogrande processing facility successfully commissioned · Taking over full operational control of the Friday Underground mining activities succesfully completed · No injuries reported in the last 12 months; LTIFR 0 (11) Financial highlights · Total revenue was 5.8 MSEK (105.3) · EBITDA was –48.8 MSEK (-5.5) · Total cash flow was -3.3 MSEK (0.4) · Earnings per share was -1.28 SEK (-1.01) Significant subsequent events ·

ColdZyme – third largest cold brand in Sweden

Q4 · Net sales reached SEK 22.2 (18.9) million. · Result after tax came in at SEK -5.3 (-7.4) million. · Earnings per share, basic and diluted, were SEK -0.04 (-0.07). · Cash and cash equivalents were SEK 29.3 (70.3) million.  Significant events during the quarter · After ending the year on a strong note, ColdZyme® surpassed Nipaxon and became the third largest cold brand in terms of sales value from pharmacies in the Swedish market, with a market share of 6.5%. In the fourth quarter, sales of ColdZyme to consu-mers increased by 7%, compared with market growth for

Pharmacolog's Year-end Bulletin 2019

Press release: Uppsala, February 13, 2020. Pharmacolog i Uppsala AB’s (publ) Year-end Bulletin 2019 is now available on the company’s webbsite www.pharmacolog.com (Swedish only)Fjärde kvartalet 1 oktober 2019 – 31 december 2019  ·Bolagets nettoomsättning för perioden uppgick till 61 (771)Tkr. ·Rörelseresultatet för perioden uppgick till -4 627 (-3 239) Tkr. ·Nettoresultat per aktie före och efter utspädning var för perioden -0,59 (-0,46) kr. Perioden 1 januari 2019 – 31 december 2019  ·Bolagets nettoomsättning för perioden uppgick till 2 182 (1 035)Tkr. ·

Swedencare AB (publ) YEAREND REPORT OCTOBER 1st – DECEMBER 31st 2019

Once again a strong year for Swedencare!SUMMARY OF THE PERIOD FOURTH QUARTER: OCTOBER 1ST – DECEMBER 31ST 2019 Numbers in parentheses refers to outcomes during the corresponding period of the previous year. · Net revenue amounted to 34,084 KSEK (27,778 KSEK), an increase of 23% · Organic, currency-adjusted growth amounted to 13% · Operating profit before depreciation (EBITDA) amounted to 8,246 KSEK (7,684 KSEK), correspondingto an increase of 7% and an EBITDA margin of 24,2% (27.7%) · Operating profit after depreciation (EBIT) amounted to 6,584 KSEK (7,332 KSEK),

Wärtsilä gas power plant will facilitate growth of Bangladeshi industrial complex

Wärtsilä Corporation, Press release, 13 February 2020 at 9.30 am EETThe technology group Wärtsilä has been awarded to supply a 78 MW engine power plant on a fast-track basis in order to support the growth of an industrial complex in Bangladesh. The order was placed in November by Jamuna Power, a part of the Jamuna Group, one of Bangladesh’s largest industrial conglomerates. The plant will be installed at the Jamuna Industrial Park project in the northeastern part of the country, and it will operate on eight Wärtsilä 34SG engines fueled by gas. The industrial park is currently operating

Viking Supply Ships AB (publ) Year-end report 2019

Press release  13 February 2020The financial net result improved by MSEK 178 from MSEK (-123) in the corresponding period in 2018 to MSEK 55 in the fourth quarter of 2019. Revenue increased to MSEK 156 (52) for the quarter, which was in line with the previous quarter. EBITDA is positive for the quarter at MSEK 63 (-51). For the full year 2019, revenue from continuing operations was MSEK 504, which is a significant improvement of the corresponding figure for 2018 (300). EBITDA for the full year 2019 was MSEK 114, while the net result was MSEK 52. Both EBITDA and net result are significant

MEDIVIR AB – YEAR END REPORT JANUARY – DECEMBER 2019

Continued progress with our proprietary and wholly owned candidate drug MIV-818 for liver cancer October – DecemberSignificant events during the quarter · Preclinical data showing that in addition to its direct effect on cancer cells, MIV-818 also modulates the anti-tumor immune response, presented at the AACR-NCI-EORTC conference in Boston. · The ninth and final liver cancer patient was included in the phase Ia study with MIV-818. Based on safety and tolerability as well as pharmaco-kinetics and positive biomarker data, it was decided to initiate the phase Ib part of the study.

Stora Enso’s Annual Report 2019 published

STORA ENSO OYJ ANNUAL FINANCIAL REPORT 13 February 2020 at 9.30 EET Stora Enso’s Annual Report 2019 has been published at storaenso.com/annualreport . The Annual Report 2019 consists of four sections: Strategy, Sustainability, Financials and Governance. Strategy explains how our transformation is progressing and how we create value as a renewable materials company, highlighting key events from all divisions. Sustainability covers Stora Enso’s social, environmental, and economic sustainability performance. Financials consists of the report of

NRC Group ASA: Key information relating to subsequent offering

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART DIRECTLY OR INDIRECTLY, IN AUSTRALIA, CANADA, JAPAN OR THE UNITED STATES OR ANYOTHER JURISDICTION IN WHICH THE RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. THIS ANNOUNCEMENT DOES NOT CONSTITUTE AN OFFER OF ANY OF THE SECURITIES DESCRIBED HEREIN. Reference is made to the stock exchange published by NRC Group ASA (the "Company") on 12 February 2020, regarding a private placement of 18,918,919 new shares in the Company (the "Private Placement") and a subsequent offering of up to 1,891,892 new shares at the same

The Nomination Committee's proposal regarding the Board of Humana for the 2020 AGM

Ahead of the Annual General Meeting 2020 the Nomination Committee of Humana AB has decided to propose Karita Bekkemellem and Anders Nyberg as new directors of the Board.The Nomination Committee proposes that the Board be composed of seven directors (unchanged from the current year) elected at the Annual General Meeting, with no alternates, for the period until the next Annual General Meeting The Nomination Committee proposes re-election of Magdalena Gerger, Kirsi Komi, Monica Lingegård, Sören Mellstig and Fredrik Strömholm as directors and election of Karita Bekkemellem and Anders Nyberg

Notice of the Annual General Meeting of Terveystalo 2020

Stock Exchange Release 13 February 2020 at 9:01 EET Notice is given to the shareholders of Terveystalo Plc of the Annual General Meeting to be held on Thursday, 2 April 2020 at 3:00 p.m. at Finlandia Hall, Mannerheimintie 13e, Helsinki, Finland. The reception of attendees, who have registered for the meeting, will commence at 2:00 p.m. A. Matters on the agenda of the Annual General Meeting The following matters will be considered at the Annual General Meeting: 1. Opening of the meeting 2. Calling the meeting to order 3. Election of persons to scrutinize the minutes and to

Citycon Oyj: Managers’ Transactions

CITYCON OYJ   Managers’ Transactions   13 February 2020 at 9:00 hrsPerson subject to the notification requirement: Arnold de Haan, Member of the BoardIssuer: Citycon Oyj, LEI 549300P8N0P6KDGTJ206Notification type: initial notificationReference number: 549300P8N0P6KDGTJ206_20200212133832_4 1) TransactionDate: 10 February 2020Venue: NASDAQ HELSINKI LTD (XHEL)Nature of the transaction: disposalInstrumentshare (CTY1S)ISIN Code: FI4000369947Transaction detailsvolume: 35,974unit price: 9.60633 EURAggregated transactionstotal volume: 35,974volume weighted average

Flexion Mobile Plc - Q3 Report 31 December 2019

Flexion hits new quarterly revenue record during the busy Black Friday and Christmas period. The third financial quarter recorded total revenue of GBP 2.5m representing 41% growth (YoY). The Company signed two new titles and announced a partnership with Huawei’s App Gallery.October 2019 to December 2019 performance · Total revenue increased by 41% to GBP 2.5m (GBP 1.8m)* · Gross profit increased by 26% to GBP 0.3m (GBP 0.2m) · Adjusted EBITDA improved by 26% to GBP -0.5m (GBP -0.7m) · Operating loss reduced by 22% to GBP -0.6m (GBP -0.7m) · Earnings per share amounted to

Viking Line: Year-End Report for the period January - December 2019

Viking Line Abp       YEAR-END REPORT               13.2.2020, 9.00 AM Viking Line doubles its earnings January–December 2019 (compared to January–December 2018) · Sales amounted to EUR 496.4 M (497.8). · Other operating revenue was EUR 0.4 M (0.3). · Operating income totalled EUR 17.4 M (9.3). · Net financial items were EUR -3.8 M (-2.8). · Income before taxes amounted to EUR 13.6 M (6.5). · Income after taxes totalled EUR 10.8 M (5.5). Fourth quarter 2019 (compared to fourth quarter 2018) · Sales amounted to EUR 115.6 M (119.8). · Operating income

OssDsign AB (publ) publishes year-end report 2019

OssDsign CEO Anders Lundqvist: “OssDsign AB finished an exciting and eventful year on a very strong note. Our strategy for, and investments in the US market, as presented in the IPO process generated the expected good results.”The fourth quarter in figures · Net sales amounted to TSEK 5 069 (4 220).  · Loss after taxes amounted to TSEK 28 641 (15 755). · Loss per share was SEK 1,6 (2,8). · Cash flow from current operations was TSEK -24 023 (-26 887).  The full year in figures · Net sales amounted to TSEK 16 873 (13 264). · Loss after taxes amounted to TSEK 84 245 (

Humana reports fourth quarter and full year 2019

A weak finish to an eventful yearQ4, October–December 2019 · Operating revenue was SEK 1,912m (1,700), an increase of 12%, of which organic growth was 0.7%. · Operating profit was SEK 71m (82), a decrease of 13%. The profit was affected by integration costs of SEK -6m (-) for Coronaria Hoiva. The effects of IFRS 16, the new accounting standard that came into effect on 1 January 2019, on operating profit amounted to SEK 16m (-). · Net profit after tax for the period amounted to SEK 18m (51). · Earnings per share for the period before and after dilution amounted to SEK 0.35 (0.

Consistent strategy provides continued profitable growth

Summary of the period, January–December 2019 · Net sales SEK 1 156 million (1 017) · EBITA SEK 247 million (212), with an EBITA margin of 21% (21) · Operating profit SEK 144 million (128), with an operating margin of 12% (13) · Profit after net financial items was SEK 130 million (117) · Earnings per share before dilution SEK 3.16 (3.23) · Cash flow from operating activities SEK 278 million (197) · The Board of Directors propose a dividend increase to SEK  1.35 per share (1.20) Summary of the period, October–December 2019 · Net sales 298 million (290) · EBITA

TOMRA: Invitation to Q4 2019 Presentation

TOMRA's fourth quarter 2019 results will be released Thursday 20[th] of February 2020. President & CEO Stefan Ranstrand and CFO Espen Gundersen will present the results at 08:00 CET (UTC+1h). The presentation will be held in English and take place at Thon Hotel Vika Atrium, Oslo Norway (Meeting room: Nyland). The presentation will also be sent via live webcast. Questions to the speakers can be directed using the Q&A-tool embedded in the webcast and will be addressed towards the end of the presentation. A recorded version of the webcast will be available shortly after the webcast

Sobi publishes report for the fourth quarter and full-year 2019

Swedish Orphan Biovitrum AB (publ)  (Sobi™) today announces its results for the fourth quarter and full-year 2019. Revenue growth for the full-year was 56 per cent with revenue of SEK 14,248 M. Adjusted EBITA was SEK 6,145 M, resulting in an adjusted EBITA margin of 43 per cent for the full year. October—December · Total revenue of SEK 4,890 M (2,571), 90 per cent revenue growth in the quarter compared with Q4 2018 (82 per cent at constant exchange rates (CER)) · Adjusted EBITA[1,2] was SEK 2,380 M (916), an increase of 160 per cent · Earnings per share (

There are no items matching the current filter
There are no more items matching the current filter
Back to top